2. Signaling Pathways
  3. Anti-infection
  4. HIV

HIV

Human immunodeficiency virus

HIV

Related Products

PDF 1.67 MB

HIV (Human immunodeficiency virus) is a lentivirus (a subgroup of retrovirus) that causes the acquired immunodeficiency syndrome (AIDS), a condition in humans in which progressive failure of the immune system allows life-threatening opportunistic infections and cancers to thrive. Infection with HIV occurs by the transfer of blood, semen, vaginal fluid, pre-ejaculate, or breast milk. Within these bodily fluids, HIV is present as both free virus particles and virus within infected immune cells. HIV infects vital cells in the human immune system such as helper T cells (specifically CD4+ T cells), macrophages, and dendritic cells. HIV infection leads to low levels of CD4+ T cells through a number of mechanisms, including apoptosis of uninfected bystander cells, direct viral killing of infected cells, and killing of infected CD4+ T cells by CD8 cytotoxic lymphocytes that recognize infected cells. When CD4+ T cell numbers decline below a critical level, cell-mediated immunity is lost, and the body becomes progressively more susceptible to opportunistic infections.

HIV Isoform Specific Products:

HIV Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-162077
    HIV-IN-10
    HIV-IN-10 is a HIV-1 latency reversing agent.
    HIV-IN-10
  • HY-15592S4
    Cabotegravir-d6
    		Inhibitor
    Cabotegravir-d6 (GSK-1265744-d6) is the deuterium labeled Cabotegravir (HY-15592). Cabotegravir (GSK-1265744) is a orally active and long-acting HIV integrase strand transfer inhibitor and organic anion transporter 1/3 (OAT1/OAT3) inhibitor with IC50 values of 2.5 nM, 0.41 μM and 0.81 μM for HIVADA, OAT3 and OAT1, respectively. Cabotegravir is primarily metabolized by uridine diphosphate glucuronosyltransferase (UGT) 1A1, with low potential to interact with other antiretroviral agents (ARVs). Cabotegravir can be used to research AIDS.
    Cabotegravir-d<sub>6</sub>
  • HY-149866
    HIV-1 inhibitor-58
    		Inhibitor
    HIV-1 inhibitor-58 (Compound 10c) is a broad-spectrum antiviral agent. HIV-1 inhibitor-58 is a non-nucleoside reverse transcriptase inhibitor. HIV-1 inhibitor-58 inhibits WT strain IIIB, NNRTI-resistant strains (such as K103N and E138K) in MT-4 cells, with EC50 less than 50 nM. HIV-1 inhibitor-58 also inhibits CYP2C9 and CYP2C19 (IC50: 2.06 μM, 1.91 μM). HIV-1 inhibitor-58 can be used for HIV infection reserch.
    HIV-1 inhibitor-58
  • HY-N19826
    Lancifodilactone N
    		Inhibitor
    Lancifodilactone N is a nortriterpenoid found in the leaves and stems of Schisandra lancifolia. Lancifodilactone N shows anti-HIV-1 activity and can be used for the research of HIV-1 infection.
    Lancifodilactone N
  • HY-12305G
    Q-VD-OPh (GMP)
    		Inhibitor
    Q-VD-OPh (GMP) is Q-VD-OPh (HY-12305) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Q-VD-OPh is an irreversible pan-caspase inhibitor with potent antiapoptotic properties; inhibits caspase 7 with an IC50 of 48 nM and 25-400 nM for other caspases including caspase 1, 3, 8, 9, 10, and 12. Q-VD-OPh can inhibits HIV infection. Q-VD-OPh is able to cross the blood-brain barrier.
    Q-VD-OPh (GMP)
  • HY-185449
    HIV RT-IN-2
    		Inhibitor
    HIV RT-IN-2 is a HIV reverse transcriptase inhibitor with an IC50 value of 1.2 μM for HIV-1 RT RNA-dependent DNA polymerase. HIV RT-IN-2 potently inhibits all three modes of HIV-1 RT-associated RNase H activity (internal, 3'-DNA directed, 5'-RNA directed cleavage) and inhibits HIV-1 replication. HIV RT-IN-2 can be used for the research of HIV-1 infection.
    HIV RT-IN-2
  • HY-179634
    ASF-006 sodium
    		Inhibitor
    ASF-006 sodium, a tetrapodal tryptophan derivative, is a potent viral invasion inhibitor. ASF-006 sodium shows potent antiviral activity against different SARS-CoV-2 Omicron variants but not against the ancestral SARS-CoV.2 strain (Wuhan-Hu-1). ASF-006 sodium competitively inhibits receptor-binding domain (RBD)-ACE2 binding via an allosteric mechanism. ASF-006 sodium inhibits Omicron BA.1, Omicron XBB.1.5, respiratory syncytial virus (RSV) and Ebola virus infection with IC50s of 0.02 μM, 0.3 μM, 1.52 μM and 0.2 μM, respectively. ASF-006 sodium inhibits cell entry of both HIV and enterovirus A71[1].
    ASF-006 sodium
  • HY-P4046
    HBV Seq2 aa:179-186
    		Inhibitor
    HBV Seq2 aa:179-186 serve as effective motifs for CTL response in H-2b system after in vitro restimulation of the primed T cells. HBV Seq2 aa:179-186 is a novel epitope identified on the surface antigen of hepatitis B virus.
    HBV Seq2 aa:179-186
  • HY-N1034
    12-Oxocalanolide A
    		Inhibitor
    12-Oxocalanolide A (compound 6) is a potent inhibitor of reverse transcriptase from human immunodeficiency virus type 1 (HIV-1) with an IC50 and EC50 of 2.8 and 12 μM, respectively. 12-Oxocalanolide A is the analogue of Calanolide.
    12-Oxocalanolide A
  • HY-125712
    CGP 53820
    		Inhibitor
    CGP 53820 is an inhibitor for HIV protease, inhibits the complex of HIV-1 and HIV-2 protease with Ki of 9 and 53 nM for HIV-1 protease and HIV-2 protease. CGP 53820 can be used in AIDS research.
    CGP 53820
  • HY-147554
    HIV-1 inhibitor-37
    		Inhibitor
    HIV-1 inhibitor-37 (Compound 83) is a potent HIV-1. HIV-1 inhibitor-37 has the potential for further development as novel latency reversing agents.
    HIV-1 inhibitor-37
  • HY-103078A
    I-XW-053 sodium
    		Inhibitor
    I-XW-053 sodium is a specific anti-HIV-1 capsid inhibitor (IC50=164.2 μM). By binding to the CA NTD-NTD hexamerization interface and the R173 region of CTD (Kd=66.3 μM), I-XW-053 sodium disrupts capsid function and reduces polymerization levels. I-XW-053 sodium effectively blocks HIV-1 uncoating, inhibits reverse transcription and early replication, and exhibits broad-spectrum activity against primary HIV-1 isolates in peripheral blood mononuclear cells. I-XW-053 sodium can be widely used in studies related to HIV-1 infection.
    I-XW-053 sodium
  • HY-P5395
    TAT-GluR23A Fusion Peptide
    		Inhibitor
    TAT-GluR23A Fusion Peptide is a biological active peptide. (This is the GluR23A sequence, a control inactive peptide used as a mutant counterpart to glutamate receptor endocytosis inhibitor (GluR23Y), connected to an 11 amino acid cell permeable HIV Trans-Activator of Transcription (TAT) protein transduction domain (PTD). GluR23A is derived from GluR23Y amino acids 869 to 877, with Ala substituted for Tyr, and thus lacking essential phosphorylation sites.Control peptide of HY-P2259)
    TAT-GluR23A Fusion Peptide
  • HY-182916
    NNRT-IN-16
    		Inhibitor
    NNRT-IN-16, Rilpivirin (HY-10574) analogue, is a non-nucleoside reverse transcriptase inhibitor (NNRTI). NNRT-IN-16 inhibits recombinant WT HIV-1 RT with an IC50 of 0.07 μM. NNRT-IN-16 exerts antiviral activity against wild-type and drug-resistant HIV-1 mutants, shows attenuated CYP isoenzyme and hERG inhibition, reduced cytotoxicity, and improved metabolic stability in human liver microsomes. NNRT-IN-16 can be used for the research of HIV-1 infection.
    NNRT-IN-16
  • HY-116528
    GCA-186
    		Inhibitor
    GCA-186 is a potent anti-HIV-1 agent. GCA-186 is highly active against both wild type and mutated HIV-1 strains with EC50s of 1, 180, 1, and 40 nM for IIIB, IIIB-R(Y181C), NL4-3 and NL4-3K103N of HIV-1 strains, respectively.
    GCA-186
  • HY-15287S1
    Nelfinavir-d4
    		Inhibitor
    Nelfinavir-d4 is deuterated labeled Nelfinavir (HY-15287). Nelfinavir (AG-1341) is a potent and orally bioavailable HIV-1 protease inhibitor (Ki=2 nM) for HIV infection. Nelfinavir is a broad-spectrum, anticancer agent.
    Nelfinavir-d<sub>4</sub>
  • HY-N6849
    InteriotherinA
    		Inhibitor
    Interiotherin A is a lignan with a dibenzocyclooctadiene skeleton isolated from Kadsura interior. Interiotherin A inhibits HIV replication to exhibit anti-HIV activity, it has a role as a metabolite and an anti-HIV agent.
    InteriotherinA
  • HY-P11407
    HIV-1 GAG peptide A-I
    HIV-1 GAG peptide A-I is a specific HIV-1 Gag peptide sequence, known to be a CD8+ T cell epitope. HIV-1 GAG peptide A-I can be used for the research of HIV vaccines..
    HIV-1 GAG peptide A-I
  • HY-144715
    HIV-1 inhibitor-17
    		Inhibitor
    HIV-1 inhibitor-18 (compound V-25i) is a potent HIV-1 capsid inhibitor with an EC50 value of 2.57 μM for HIV-1 NL4-3. HIV-1 inhibitor-18 has certain cytotoxicity (MT-4 cells CC50 >8.55).
    HIV-1 inhibitor-17
  • HY-105372
    PNU-103657
    		Inhibitor
    PNU-103657 (Compound 13) is an orally active reverse transcriptase inhibitor (IC50 = 0.51 μM (WT)). PNU-103657 has antiviral activity. PNU-103657 can be used in research on infections and immune system diseases such as HIV infection.
    PNU-103657
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity
HIV Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.